At a glance
ClinicalIndex Comparison RecordPhase 2Active· 29 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Prostate Cancer. Active but no longer recruiting, targeting 29 participants across 5 sites.
Detailed Summary
This research study is studying an immune-based cancer drug as a possible treatment for prostate cancer. The drug involved in this study is: -Nivolumab
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb, Dana-Farber Cancer Institute
Timeline
Phase 2Active
201920202021202220232024202520262027
First PostedAug 2018
Enrollment StartOct 2018
Primary CompletionSep 2023
TodayJul 2026
Study CompletionDec 2026
First PostedAug 20, 2018
Enrollment StartOct 18, 2018
Primary CompletionSep 30, 2023
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 7.9 years ago
Interventions
Nivolumabdrug
Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer